Reach Us +44-1904-929220
188Re-Lanreotide: Determination Of Radiopharmacokinetics Parameters In Rats | 3692

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

188Re-Lanreotide: Determination of radiopharmacokinetics parameters in rats

2nd World Congress on Biomarkers & Clinical Research

Eva M. Molina-Trinidad, Consuelo Arteaga de Murphy, Helgi Jung-Cook, Eduardo Murphy Stack, Martha Pedraza- L?pez, Jos? Luis Morales- M?rquez, Guadalupe Vertiz Serrano

Posters: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.3

Background: We used 188Re-lanreotide to determine its radiopharmaceutical parameters in a model of Wistar rats with induced hepatocellular carcinoma, aft er a single intravenous dose. Th e rat model is useful to determine the pharmacokinetic parameters and the tumor/organ ratios of 188Re-lanreotide to be used for calculating the personal dose following the methodology MIRDOSE and later in the diagnosis and therapy of cancer. Objetive: We used 188Re-lanreotide to determine radiopharmaceutical parameters in a model in rats Wistar. Methods: 188Re labeled by a modifi ed direct method. AS-30D hepatoma cells were obtained from ascites of a Wistar rat with hepatoma. Healthy and tumor induced hepatocellular carcinoma Wistar rats were used for distribution and radiopharmacokinetic studies. 188Re-lanreotide, ≈1.8 MBq in 0.1 mL was injected in the peritoneal cavity and in the dorsal left side of healthy rats. Th e rats were sacrifi ced at 0.083, 0.25, 0.5, 1.16, 3 and 24 h post injection. Th e activity (%IA/g) of all the blood samples in the following times: 0.25, 0.5, 1.1, 3, 5, 8, 12, 15, 18, and 24 h for healthy rats and 0.25, 0.5, 1.16, 3, and 24 h for hepatoma induced rats. Results: Th e radiopharmacokinetic parameters were calculated following a two-compartment, fi rst-order elimination model of 188Re-lanreotide in healthy rats and for rats with induced tumor using the WinNonlin program. Conclusion: A pharmacokinetic profi le of 188Re-lanreotide in healthy and hepatoma tumor induced rats follow model two-compartment. With mean residence time and the mean half life we will be calculate the therapeutic dose following MIRDOSE methodology
Relevant Topics